HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Risendronate Sodium Intelligence Report

Intelligence report

Intelligence Report · ~10 min read

Risendronate Sodium Intelligence Report

Aurobindo Pharma · Bone Health · Bisphosphonate · Approved

Type

Asset Intelligence Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 69%

Evidence

27 items

Sources

20

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

The FDA's grant of Abbreviated Approval status to Aurobindo Pharma for Risendronate Sodium signifies a new competitive entrant in the bisphosphonate market. This could impact pricing and market share for existing therapies, necessitating strategic adjustments by current market players. Regulatory context from FDA (FDA AP — RISEDRONATE SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 27 ranked evidence items (14 high-relevance).

Key Developments

Material intelligence events ranked by strategic relevance.

  1. watchJun 23, 2026

    Aurobindo Pharma's Risendronate Sodium Approval Signals Increased Bisphosphonate Competition

    Monitor for the launch timeline of Aurobindo's Risendronate Sodium and subsequent market responses from competitors.

    View detail
  2. watchJun 23, 2026

    Aurobindo Pharma's Risendronate Sodium Approval Signals Increased Bisphosphonate Competition

    Any timeline shifts beyond the near term would change the urgency of strategic adjustments.

    View detail
  3. watchJun 23, 2026

    Aurobindo Pharma's Risendronate Sodium Approval Signals Increased Bisphosphonate Competition

    A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure significantly.

    View detail
  4. watchJun 23, 2026

    Aurobindo Pharma's Risendronate Sodium Approval Signals Increased Bisphosphonate Competition

    This becomes more urgent if Monitor for the launch timeline and any subsequent market responses from competitors.

    View detail
  5. regulatoryJun 23, 2026

    FDA AP — DIVALPROEX SODIUM (SUPPL)

    Application ANDA077567. Sponsor: MYLAN. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: DIVALPROEX SODIUM.

    View detail
  6. regulatoryJun 23, 2026

    FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

    Application NDA209552. Sponsor: EUGIA PHARMA SPECLTS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    View detail
  7. regulatoryJun 23, 2026

    FDA AP — METHOTREXATE SODIUM (SUPPL)

    Application NDA008085. Sponsor: STRIDES PHARMA INTL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: METHOTREXATE SODIUM.

    View detail
  8. regulatoryJun 23, 2026

    FDA AP — METHOTREXATE SODIUM (SUPPL)

    Application NDA008085. Sponsor: STRIDES PHARMA INTL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: METHOTREXATE SODIUM.

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for similar products. The strongest clinical anchor is A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Bone Health · Bisphosphonate, 8 regulatory and 6 competitive items passed relevance filtering for Aurobindo Pharma. This becomes more urgent if Monitor for the launch timeline and any subsequent market responses from competitors. Timeline shift beyond near term would change urgency. A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — RISEDRONATE SODIUM (SUPPL)

    FDA

    Source: FDA

    View evidence

  • FDA AP — ALENDRONATE SODIUM (SUPPL)

    FDA

    Source: FDA

    View evidence

  • FDA AP — DIVALPROEX SODIUM (SUPPL)

    FDA

    Source: FDA

    View evidence

  • FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

    FDA

    Source: FDA

    View evidence

  • FDA AP — METHOTREXATE SODIUM (SUPPL)

    FDA

    Source: FDA

    View evidence

  • FDA AP — METHOTREXATE SODIUM (SUPPL)

    FDA

    Source: FDA

    View evidence

  • FDA AP — METHOTREXATE SODIUM (SUPPL)

    FDA

    Source: FDA

    View evidence

  • FDA AP — DIVALPROEX SODIUM (SUPPL)

    FDA

    Source: FDA

    View evidence

  • FDA AP — RISEDRONATE SODIUM (SUPPL)

    high relevance

    Application ANDA200296. Sponsor: AUROBINDO PHARMA LTD. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: RISEDRONATE SODIUM.

    Source: FDA

    View evidence

  • FDA AP — ALENDRONATE SODIUM (SUPPL)

    high relevance

    Application ANDA090124. Sponsor: AUROBINDO PHARMA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ALENDRONATE SODIUM.

    Source: FDA

    View evidence

  • FDA AP — DIVALPROEX SODIUM (SUPPL)

    high relevance

    Application ANDA217358. Sponsor: MANKIND PHARMA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: DIVALPROEX SODIUM.

    Source: FDA

    View evidence

  • FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

    high relevance

    Application NDA209552. Sponsor: EUGIA PHARMA SPECLTS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    Source: FDA

    View evidence

  • FDA AP — METHOTREXATE SODIUM (SUPPL)

    high relevance

    Application ANDA210454. Sponsor: EUGIA PHARMA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: METHOTREXATE SODIUM.

    Source: FDA

    View evidence

  • FDA AP — METHOTREXATE SODIUM (SUPPL)

    high relevance

    Application NDA008085. Sponsor: STRIDES PHARMA INTL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: METHOTREXATE SODIUM.

    Source: FDA

    View evidence

  • FDA AP — METHOTREXATE SODIUM (SUPPL)

    high relevance

    Application NDA008085. Sponsor: STRIDES PHARMA INTL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: METHOTREXATE SODIUM.

    Source: FDA

    View evidence

  • FDA AP — DIVALPROEX SODIUM (SUPPL)

    high relevance

    Application ANDA214643. Sponsor: UNICHEM. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: DIVALPROEX SODIUM.

    Source: FDA

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Aurobindo Pharma's Risendronate Sodium ANDA Submission Receives AP Status

    Regulatory Approval

Insights

  • Aurobindo Pharma's Risendronate Sodium Approval Signals Increased Bisphosphonate Competition

    Bone Health · Bisphosphonate

Companies

  • Aurobindo Pharma

    Sponsor

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.